Form 8-K

0001171843-24-002784.txt : 20240513 0001171843-24-002784.hdr.sgml : 20240513 20240513080036 ACCESSION NUMBER: 0001171843-24-002784 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240513 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240513 DATE AS OF CHANGE: 20240513 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Compass Therapeutics, Inc. CENTRAL INDEX KEY: 0001738021 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39696 FILM NUMBER: 24936938 BUSINESS ADDRESS: STREET 1: 80 GUEST STREET CITY: BOSTON STATE: MA ZIP: 02135 BUSINESS PHONE: 617-500-8099 MAIL ADDRESS: STREET 1: 80 GUEST STREET CITY: BOSTON STATE: MA ZIP: 02135 FORMER COMPANY: FORMER CONFORMED NAME: Olivia Ventures, Inc. DATE OF NAME CHANGE: 20180419 8-K 1 f8k_051124.htm FORM 8-K Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 13, 2024

_______________________________

Compass Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

_______________________________

Delaware	001-39696	82-4876496
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

80 Guest Street, Suite 601

Boston, Massachusetts 02135

(Address of Principal Executive Offices) (Zip Code)

(617) 500-8099

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value per share	CMPX	NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On May 13, 2024, Compass Therapeutics, Inc. issued a press release announcing financial results for the quarter ended March 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Exhibit

99.1		Press Release dated May 13, 2024 (furnished pursuant to Item 2.02)
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Compass Therapeutics, Inc.


Date: May 13, 2024	By:	/s/ Neil Lerner
		Neil Lerner
		VP Finance

EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling

EXHIBIT 99.1

Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update

Received FDA Fast Track Designation for the investigation of CTX-009 in combination with paclitaxel for the treatment of patients with metastatic or locally advanced biliary tract tumors.

Enrollment is progressing well in COMPANION-002, a Phase 2/3 randomized study of CTX-009 (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC). Enrollment is expected to be completed by mid-year 2024 with top-line data expected in the first quarter of 2025.
Completed enrollment of patients in COMPANION-003, a Phase 2 study of CTX-009 in patients with advanced colorectal cancer (CRC); top-line data from Stage 1 are expected by mid-year 2024.
Enrollment in the Phase 1b combination study of CTX-471 (CD137 agonist antibody) and KEYTRUDA^® in patients with non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) and melanoma is ongoing.
Advanced CTX-8371 (PD-1 x PD-L1 bispecific antibody) into a first-in-human clinical study and dosed the first patient in April.
Initiated planning of a Phase 2 monotherapy study of CTX-471 in patients with advanced melanoma whose tumors express a newly identified biomarker of CTX-471 activity.
Ended the first quarter with $156 million in cash and marketable securities, which is expected to provide cash runway into late 2026.

BOSTON, May 13, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported first quarter 2024 financial results and provided a business update.

“Compass continues to make considerable progress across all of our clinical programs, with the recently announced receipt of FDA Fast Track Designation for CTX-009, showcasing the large unmet need in patients with advanced BTC where current therapies have low, single digit response rates, and limited effects on patient survival,” said Vered Bisker-Leib, PhD, Chief Executive Officer.

"We are excited that we are less than a year from reporting top-line data from COMPANION-002, our Phase 2/3 study in patients with BTC. By mid-year, we plan to report top-line data from the first part of COMPANION-003, our Phase 2 study in patients with advanced CRC. Finally, we will embark on COMPANION-004, our study of CTX-009 in a third indication. We also continue to advance CTX-471, our CD137 agonistic antibody and CTX-8371, our novel bispecific checkpoint blocker. Recently, we discovered a potential biomarker of activity of CTX-471, and preparations are underway for a Phase 2 study of CTX-471 in patients with melanoma,” added Thomas Schuetz, MD, PhD, President of R&D and Vice Chair of Compass Board.

Development Pipeline Updates:

CTX-009 (DLL4 and VEGF-A bispecific antibody)

Continuing to enroll patients in COMPANION-002, a U.S. Phase 2/3 randomized study of CTX-009 in combination with paclitaxel in patients with advanced BTC.
- Received FDA Fast Track Designation.
- The primary endpoint of the study is overall response rate, and secondary endpoints include progression free survival, overall survival, clinical benefit rate and duration of response.
- Enrollment is expected to be completed by mid-year 2024 with top-line data expected in the first quarter of 2025.
Completed enrollment of Stage 1 of COMPANION-003, a U.S. Phase 2 study of CTX-009 as a monotherapy in patients with advanced, metastatic CRC.
- The study design is an Adaptive Simon Two-Stage. Stage 1 of the study is designed to enroll 37 evaluable patients with CRC who have received two or three prior systemic therapies irrespective of their KRAS mutation status.
- In line with prior guidance, top-line data from Stage 1 is expected by mid-year 2024.
- If adequate efficacy is observed in Stage 1, the study will continue to Stage 2 where 47 additional patients are expected to be enrolled.

CTX-471 (CD137 agonist antibody)

CTX-471 is a CD137 agonist antibody, which binds to a unique epitope of the co-stimulatory molecule 4-1BB with an optimized affinity.
In the Phase 1b monotherapy study, five responses were observed, all in patients who previously received checkpoint inhibitors. A durable partial response (PR) in a patient with SCLC converted to a complete response, as confirmed by a PET scan. Additionally, the objective response rate in the subset of patients with advanced melanoma was 27% (3 of 11). The fifth response occurred in a patient with mesothelioma.
Ongoing analysis of biopsy specimens from the Phase 1b study revealed a potential biomarker of response. As a result, planning for a Phase 2 monotherapy study in patients with melanoma whose tumors express this biomarker is underway.
Enrollment is ongoing of up to 60 patients in the Phase 1b dose-expansion cohort of the combination arm of CTX-471 and Merck’s anti-PD-1 therapy KEYTRUDA^® (pembrolizumab) with melanoma, non-small cell lung cancer and small cell lung cancer, who will be randomly assigned to one of two doses.

CTX-8371 (PD-1 x PD-L1 bispecific antibody)

CTX-8371 is a next generation bispecific checkpoint inhibitor that simultaneously targets PD-1 and PD-L1 and exhibits a unique mechanism-of-action that involves cleavage of cell surface PD-1.
In April 2024, the first patient in this study was dosed; dosing of additional patients and opening additional clinical sites is in progress.

Financial Results

Net loss for the quarter ended March 31, 2024, was $10.8 million or $0.08 per share of common stock, compared to $7.8 million or $0.06 per share of common stock for the same period in 2023.

Research and Development (R&D) Expenses

R&D expenses were $9.5 million for the quarter ended March 31, 2024, as compared to $6.6 million for the same period in 2023, an increase of $2.9 million. This increase was primarily attributable to a $2.2 million increase in clinical costs related to the lead program, CTX-009.

General and Administrative (G&A) Expenses

G&A expenses were $3.2 million for the quarter ended March 31, 2024, as compared to $3.1 million for the same period in 2023.

Cash Position

As of March 31, 2024, cash and marketable securities were $156.3 million as compared to $152.5 million as of December 31, 2023, extending our cash runway into late 2026.

During the first quarter of 2024, Compass increased its cash position by $3.8 million, primarily from $18.0 million cash received from issuance of stock through its at-the-market offering program, partially offset by $13.9 million of net cash used in operating activities.

About Compass Therapeutics
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at https://www.compasstherapeutics.com.

Forward-Looking Statements
This press release contains forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to Compass’s financial position to continue advancing its product candidates, expectations about cash runway, business and development plans, and statements regarding Compass’s product candidates, including their development and clinical trial milestones such as the expected trial design, timing of enrollment, patient dosing and data readouts, regulatory plans with respect to Compass’s product candidates and the therapeutic potential thereof. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, Compass’s ability to raise the additional funding it will need to continue to pursue its business and product development plans, the inherent uncertainties associated with developing product candidates and operating as a development stage company, Compass’s ability to identify additional product candidates for development, Compass’s ability to develop, complete clinical trials for, obtain approvals for and commercialize any of its product candidates, competition in the industry in which Compass operates and market conditions. These forward-looking statements are made as of the date of this press release, and Compass assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents Compass files with the U.S. Securities and Exchange Commission (SEC) available at www.sec.gov, including without limitation Compass’s latest Annual Report on Form 10-K, Quarterly Report on Form 10-Q and subsequent filings with the SEC.

Investor Contact
ir@compasstherapeutics.com

Media Contact
Anna Gifford, Senior Manager of Communications
media@compasstherapeutics.com
617-500-8099


Compass Therapeutics, Inc. and Subsidiaries Condensed Consolidated Statements of Operations (In thousands, except per share data)

	Three Months Ended March 31,
	2024			2023
	(unaudited)
Operating expenses:
Research and development	$	9,522		$	6,638
General and administrative	3,248			3,073
Total operating expenses	12,770			9,711
Loss from operations	(12,770		)	(9,711		)
Other income	1,983			1,874
Loss before income tax expense	(10,787		)	(7,837		)
Income tax expense	—			—
Net loss	$	(10,787	)	$	(7,837	)
Net loss per share - basic and diluted	$	(0.08	)	$	(0.06	)
Basic and diluted weighted average shares outstanding	136,608			126,375

Compass Therapeutics, Inc. and Subsidiaries Condensed Consolidated Balance Sheets (In thousands)

	March 31, 2024		December 31, 2023
	(unaudited)
Assets
Current assets:
Cash and cash equivalents	$	23,674	$	24,228
Marketable securities		132,581		128,233
Prepaid expenses and other current assets		2,356		1,420
Total current assets		158,611		153,881
Property and equipment, net		744		898
Operating lease, right-of-use ("ROU") asset		1,467		1,776
Other assets		320		320
Total assets	$	161,142	$	156,875
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable	$	854	$	4,090
Accrued expenses		1,815		2,514
Operating lease obligations, current portion		1,224		1,197
Total current liabilities		3,893		7,801
Operating lease obligations, long-term portion		189		536
Total liabilities		4,082		8,337
Total stockholders' equity		157,060		148,538
Total liabilities and stockholders' equity	$	161,142	$	156,875

EX-101.SCH 3 gnw-20190101.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 gnw-20190101_def.xml XBRL DEFINITION FILE EX-101.LAB 5 gnw-20190101_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 gnw-20190101_pre.xml XBRL PRESENTATION FILE XML 8 R1.htm IDEA: XBRL DOCUMENT

Cover	May 13, 2024
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	May 13, 2024
Entity File Number	001-39696
Entity Registrant Name	Compass Therapeutics, Inc.
Entity Central Index Key	0001738021
Entity Tax Identification Number	82-4876496
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	80 Guest Street, Suite 601
Entity Address, City or Town	Boston
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02135
City Area Code	617
Local Phone Number	500-8099
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	CMPX
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false

EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://globenewswire.com/role/Cover Cover Cover 1 false false All Reports Book All Reports f8k_051124.htm gnw-20190101.xsd gnw-20190101_def.xml gnw-20190101_lab.xml gnw-20190101_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "f8k_051124.htm": { "nsprefix": "gnw", "nsuri": "http://globenewswire.com/20190101", "dts": { "inline": { "local": [ "f8k_051124.htm" ] }, "schema": { "local": [ "gnw-20190101.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "definitionLink": { "local": [ "gnw-20190101_def.xml" ] }, "labelLink": { "local": [ "gnw-20190101_lab.xml" ] }, "presentationLink": { "local": [ "gnw-20190101_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://globenewswire.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Form8K", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "body", "html" ], "reportCount": 1, "baseRef": "f8k_051124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Form8K", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "body", "html" ], "reportCount": 1, "baseRef": "f8k_051124.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001171843-24-002784-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-24-002784-xbrl.zip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f8k_051124_htm.xml IDEA: XBRL DOCUMENT 0001738021 2024-05-13 2024-05-13 iso4217:USD shares iso4217:USD shares 0001738021 false 8-K 2024-05-13 Compass Therapeutics, Inc. DE 001-39696 82-4876496 80 Guest Street, Suite 601 Boston MA 02135 617 500-8099 false false false false Common Stock, $0.0001 par value per share CMPX NASDAQ true false